Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 0.87.

  • Viridian Therapeutics, Inc.\DE's Equity Ratio fell 491.77% to 0.87 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.87, marking a year-over-year decrease of 491.77%. This contributed to the annual value of 0.9 for FY2024, which is 37.46% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Equity Ratio stood at 0.87 for Q3 2025, which was down 491.77% from 0.88 recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Equity Ratio peaked at 0.93 during Q3 2022, and registered a low of 0.84 during Q2 2022.
  • For the 5-year period, Viridian Therapeutics, Inc.\DE's Equity Ratio averaged around 0.9, with its median value being 0.9 (2024).
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Equity Ratio skyrocketed by 4431.62% in 2021, and later plummeted by 708.44% in 2023.
  • Viridian Therapeutics, Inc.\DE's Equity Ratio (Quarter) stood at 0.92 in 2021, then dropped by 1.46% to 0.91 in 2022, then fell by 0.74% to 0.9 in 2023, then rose by 0.37% to 0.9 in 2024, then dropped by 3.67% to 0.87 in 2025.
  • Its Equity Ratio stands at 0.87 for Q3 2025, versus 0.88 for Q2 2025 and 0.91 for Q1 2025.